[go: up one dir, main page]

WO2008002929A3 - Heterologous cross-sensitization for improved agonist activity - Google Patents

Heterologous cross-sensitization for improved agonist activity Download PDF

Info

Publication number
WO2008002929A3
WO2008002929A3 PCT/US2007/072147 US2007072147W WO2008002929A3 WO 2008002929 A3 WO2008002929 A3 WO 2008002929A3 US 2007072147 W US2007072147 W US 2007072147W WO 2008002929 A3 WO2008002929 A3 WO 2008002929A3
Authority
WO
WIPO (PCT)
Prior art keywords
sensitization
agonist activity
heterologous cross
improved agonist
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/072147
Other languages
French (fr)
Other versions
WO2008002929A2 (en
Inventor
Richard A Bond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inverseon Inc
Original Assignee
Inverseon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inverseon Inc filed Critical Inverseon Inc
Publication of WO2008002929A2 publication Critical patent/WO2008002929A2/en
Publication of WO2008002929A3 publication Critical patent/WO2008002929A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods for improving the effectiveness of prostacyclin agonists by heterologous sensitization by co-administering beta adrenergic inverse agonists are provided for the treatment of pulmonary hypertension and other diseases treated by chronic prostacyclin treatment.
PCT/US2007/072147 2006-06-26 2007-06-26 Heterologous cross-sensitization for improved agonist activity Ceased WO2008002929A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81668706P 2006-06-26 2006-06-26
US60/816,687 2006-06-26

Publications (2)

Publication Number Publication Date
WO2008002929A2 WO2008002929A2 (en) 2008-01-03
WO2008002929A3 true WO2008002929A3 (en) 2008-07-10

Family

ID=38846479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072147 Ceased WO2008002929A2 (en) 2006-06-26 2007-06-26 Heterologous cross-sensitization for improved agonist activity

Country Status (1)

Country Link
WO (1) WO2008002929A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20060104913A1 (en) * 2003-06-27 2006-05-18 Merck Patent Gmbh Inhalable formulations for treating pulmonary hypertension and methods of using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060104913A1 (en) * 2003-06-27 2006-05-18 Merck Patent Gmbh Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIGGIN ET AL.: "Investigation of the Mechanism of G Protein: Effector Coupling by the Human and Mouse Prostacyclin Receptors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, 2002, pages 27053 - 27064 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339139B2 (en) 2013-01-11 2022-05-24 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11046666B2 (en) 2013-01-11 2021-06-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US12365663B2 (en) 2013-01-11 2025-07-22 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11958822B2 (en) 2013-01-11 2024-04-16 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9776982B2 (en) 2013-01-11 2017-10-03 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9845305B2 (en) 2013-01-11 2017-12-19 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10752605B2 (en) 2013-01-11 2020-08-25 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11505535B2 (en) 2013-01-11 2022-11-22 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10344012B2 (en) 2013-01-11 2019-07-09 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10450290B2 (en) 2013-01-11 2019-10-22 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11802105B2 (en) 2015-06-17 2023-10-31 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10759733B2 (en) 2015-06-17 2020-09-01 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10703706B2 (en) 2015-06-17 2020-07-07 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10988435B2 (en) 2015-06-17 2021-04-27 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11034645B2 (en) 2015-06-17 2021-06-15 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10464877B2 (en) 2015-06-17 2019-11-05 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11407707B2 (en) 2015-06-17 2022-08-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10246403B2 (en) 2015-06-17 2019-04-02 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10053414B2 (en) 2015-06-17 2018-08-21 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11866402B2 (en) 2015-06-17 2024-01-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9701616B2 (en) 2015-06-17 2017-07-11 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Also Published As

Publication number Publication date
WO2008002929A2 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
WO2009129433A3 (en) Alpha adrenergic receptor agonists for treatment of degenerative disc disease
WO2008097277A3 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
MX2009009592A (en) Aminopyridines useful as inhibitors of protein kinases.
MA28739B1 (en) N- (1- (1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND ASSOCIATED COMPOUNDS AS FUNGAL KINESIN PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2005082343A3 (en) Amines and amides for the treatment of diseases
MX2009008253A (en) Kinase inhibitors.
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
WO2007149427A3 (en) Tyrosine kinase inhibitors
MX2009006345A (en) Compounds useful as protein kinase inhibitors.
WO2006105527A3 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2006119467A3 (en) Protein activity modification
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
MY149630A (en) Antibodies against amyloid-beta peptide
EP2592073A3 (en) Human protein tyrosine phosphatase inhibitors and their use
EP2425849A3 (en) Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
ZA200708748B (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
MX2009010127A (en) N-heterocyclic compounds useful as inhibitors of janus kinases.
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
MY159244A (en) Method of reducing intraocular pressure in humans
PT2235060T (en) B-cell depleting agents, like anti-cd20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
WO2009114729A3 (en) Compounds, compositions and methods for treating lysosomal storage diseases and disorders
WO2008002929A3 (en) Heterologous cross-sensitization for improved agonist activity
TW200733974A (en) Materials and methods for treating chronic fibrotic disease
WO2007084651A3 (en) Methods and kits to treat chronic inflammatory immune diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799046

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07799046

Country of ref document: EP

Kind code of ref document: A2